The Effect of Walking Meditation Training on Glycemic Control and Vascular Function in Patients With Type 2 Diabetes
2015年9月15日 更新者:Assoc. Prof. Dr.Daroonwan Suksom、Chulalongkorn University
THE EFFECT OF WALKING MEDITATION TRAINING ON GLYCEMIC CONTROL AND VASCULAR FUNCTION IN PATIENTS WITH TYPE 2 DIABETES
Walking Meditation training would yield more favorable adaptations than walking alone in improving glycemic control and vascular function in patients with type 2 diabetes.
研究概览
研究类型
介入性
注册 (实际的)
33
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Samut Prakan
-
Prapadang、Samut Prakan、泰国、10130
- The Primary Health Promoting Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
40年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- The inclusion criteria included type 2 diabetes (as defined by the American Diabetes Association), a baseline glycosylated hemoglobin (HbA1c) value of 7-9%, and no previous exercise training in the past 6 months. All participants were free from diabetic nephropathy, diabetic retinopathy, severe diabetic neurophathy, severe cardiovascular and cerebrovascular diseases.
Exclusion Criteria:
- Participants were excluded if they dropped out or completed less than 80% of the training schedule.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Walking meditation & Walking
|
Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation.
The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced "Budd" and "Dha" with each foot step that contacted the floor to practice mindfulness while walking.
Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate).
In both phases the training will be performed for 30 minutes, 3 times per week.
其他名称:
Walking training program will be based on aerobic walking exercise.
The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate).
In both phases the training will be performed for 30 minutes, 3 times per week.
|
有源比较器:Walking meditation & No exercise
|
Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation.
The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced "Budd" and "Dha" with each foot step that contacted the floor to practice mindfulness while walking.
Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate).
In both phases the training will be performed for 30 minutes, 3 times per week.
其他名称:
Sedentary life style.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change from baseline in glycemic control
大体时间:Baseline, Week 12
|
The glycemic control will be quantified using blood samples.
Fasting blood glucose, HbA1c, and insulin will be measured with standard procedures at the clinical laboratory (Bria Lab, Bangkok, Thailand).Homeostasis model assessment (HOMA), the parameter for insulin resistance, will be calculated by using equation of [Fasting glucose (mg/dL) × Insulin level (uU/mL) / 405].
|
Baseline, Week 12
|
Change from baseline in vascular reactivity
大体时间:baseline, week 12
|
Vascular reactivity or brachial artery flow-mediated dilatation (FMD) will be assessed with the ultrasound equipment (CX50, Philips, USA), using the blood occlusion technique on the right forearm.
The brachial artery will be imaged above the antecubital fossa in the longitudinal plane.
Baseline data will be monitored and the cuff placed around the right forearm will be inflated to 50 mmHg above systolic blood pressure for 5 minutes and then deflated for 5 minutes of recovery.
FMD will be calculated from the formula FMD=(D2-D1)x100/D1 when D1 is the brachial artery diameter at baseline, D2 is the maximal post-occlusion brachial artery diameter
|
baseline, week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change from baseline in stress indicators
大体时间:Baseline, Week 12
|
|
Baseline, Week 12
|
Change from baseline in physical fitness
大体时间:Baseline, Week 12
|
|
Baseline, Week 12
|
Change from baseline in Peripheral arterial stiffness
大体时间:Baseline, Week 12
|
Pulse wave velocity measurement will be assessed with MD6 bidirectional transcutaneous Doppler probe (Hokanson, Bellevue, WA, USA).
All subjects were monitored with an EKG and PWV measurements in the computer and used as timing markers for PWV identification.
|
Baseline, Week 12
|
Change from baseline in ankle-brachial index.
大体时间:Baseline, Week 12
|
Ankle-brachial index will be evaluated with a manual MD6 bidirectional transcutaneous Doppler probe (Hokanson, Bellevue, WA, USA) and will be calculated by dividing the highest ankle systolic blood pressure by the highest brachial systolic blood pressure.
|
Baseline, Week 12
|
Change from baseline in blood chemistry
大体时间:Baseline, Week 12
|
|
Baseline, Week 12
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Daroonwan Suksom, Ph.D.、Faculty of Sports Science, Chulalongkorn University
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
有用的网址
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2013年12月1日
初级完成 (实际的)
2014年10月1日
研究完成 (实际的)
2015年2月1日
研究注册日期
首次提交
2014年4月18日
首先提交符合 QC 标准的
2014年4月25日
首次发布 (估计)
2014年4月28日
研究记录更新
最后更新发布 (估计)
2015年9月16日
上次提交的符合 QC 标准的更新
2015年9月15日
最后验证
2013年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
2型糖尿病的临床试验
-
Jin-Hee AhnAsan Medical Center未知HER-2基因扩增 | HER-2 蛋白过表达
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.未知
-
AIM Vaccine Co., Ltd.Ningbo Rongan Biological Pharmaceutical Co. Ltd.; LiveRNA Therapeutics Inc.招聘中
-
AIM Vaccine Co., Ltd.Ningbo Rongan Biological Pharmaceutical Co. Ltd.; LiveRNA Therapeutics Inc.尚未招聘SARS-CoV-2
-
Ridgeback Biotherapeutics, LPMerck Sharp & Dohme LLC完全的
-
Peking UniversityCenters for Disease Control and Prevention, China; Beijing Pinggu District Hospital; Peking University...完全的
Walking Meditation的临床试验
-
Rigshospitalet, DenmarkNovo Nordisk A/S; Copenhagen University Hospital at Herlev; Danish Cancer Society; TrygFonden, Denmark完全的